Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-)ganciclovir

Transplantation

Volumn 100, Issue 4, 2016, Pages 862-870

  Höcker, Britta ^a   Zencke, Sebastian ^a   Krupka, Kai ^a   Fichtner, Alexander ^a   Pape, Lars ^b   Strologo, Luca Dello ^c   Guzzo, Isabella ^c   Topaloglu, Rezan ^d   Kranz, Birgitta ^e   König, Jens ^e   Bald, Martin ^f   Webb, Nicholas J A ^g   Noyan, Aytül ^h   Dursun, Hasan ^h   Marks, Stephen ⁱ   Yalcinkaya, Fatos ^j   Thiel, Florian ^k   Billing, Heiko ^l   Pohl, Martin ^m   Fehrenbach, Henry ⁿ   Bruckner, Thomas ^o   Tönshoff, Burkhard ^a   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d HACETTEPE UNIVERSITY   (Turkey)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f Olga Children's Hospital   (Germany)

^g ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^h BASKENT UNIVERSITY   (Turkey)

ⁱ GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^j ANKARA UNIVERSITY   (Turkey)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ Children's Hospital   (Germany)

^o UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHEMOPROPHYLAXIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NONHUMAN; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE; VIRUS REPLICATION; ADOLESCENT; ADVERSE EFFECTS; AGE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION; DRUG EFFECTS; EUROPE; GRAFT SURVIVAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MULTICENTER STUDY; OPPORTUNISTIC INFECTIONS; PATHOGENICITY; PRESCHOOL CHILD; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTIONS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961912450     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000888     Document Type: Article

References (42)

1. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant. 2007;21: 149-158.
2. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation. 2000;70:1166-1174.
3. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66:329-337.
4. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pedi-atric renal transplantation. Pediatr Transplant. 2007;11:187-195.
5. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant. 2014;14 (Suppl 1):11-44.
6. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620.
7. Hodson EM, Barclay PG, Craig JC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2005;2:Cd003774.
8. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228-1237.
9. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACTstudy. Transplantation. 2010;90:1427-1431.
10. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636-643.
11. Pescovitz MD. Valganciclovir: recent progress. Am J Transplant. 2010;10: 1359-1364.
12. Plotnicki L, Kohl CD, Hocker B, et al. The CERTAIN Registry:a novel, web-based registry and research platform for pediatric renal transplantation in Europe. Transplant Proc. 2013;45:1414-1417.
13. Ljungman P, Plotkin S. CMV definitions and new syndromes. In: Ehrnst A, Ljungman P, eds. Proceedings from the 5th International Cytomegalovirus Conference (Stockholm). Scand J Infect Dis. 1995;99(Suppl): 87.
14. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
15. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop oncytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005;5:218-227.
16. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262-274.
17. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333-360.
18. Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol. 1998;9:1697-1708.
19. Filler G, Lampe D, von Bredow MA, et al. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr Nephrol. 1998;12:6-9.
20. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832-1843.
21. Hocker B, Fickenscher H, Delecluse HJ, et al. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis. 2013;56:84-92.
22. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723.
23. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementationofBanff working groups.Am J Transplant. 2010;10:464-471.
24. Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005;68: 1834-1839.
25. Smith JM, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol. 2010;21:1579-1586.
26. Smith JM, Dharnidharka VR. Viral surveillance and subclinical viral infection in pediatric kidney transplantation. Pediatr Nephrol. 2015;30:741-748.
27. Helantera I, Loginov R, Koskinen P, et al. Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol Dial Transplant. 2005;20:790-796.
28. Helantera I, Teppo AM, Koskinen P, et al. Increased urinary excretion of transforming growth factor-beta(1) in renal transplant recipients during cytomegalovirus infection. Transpl Immunol. 2006;15:217-221.
29. Dzabic M, Rahbar A, Yaiw KC, et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis. 2011;53:969-976.
30. Shimamura M, Murphy-Ullrich JE, Britt WJ. Human cytomegalovirus induces TGF-beta1 activation in renal tubular epithelial cells after epithelial-to-mesenchymal transition. PLoS Pathog. 2010;6:e1001170.
31. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002;2:850-856.
32. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8:975-983.
33. Smedbraten YV, Sagedal S, Leivestad T, et al. The impact of early cyto-megalovirus infection after kidney transplantation on long-term graft and patient survival. Clin Transplant. 2014;28:120-126.
34. Danziger-Isakov LA, DelaMorena M, Hayashi RJ, et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation. 2003;75:1538.
35. Danziger-Isakov LA, Worley S, Michaels MG, et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation. 2009;87:1541-1548.
36. Florescu DF, Langnas AN, Grant W, et al. Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients. Pediatr Transplant. 2012;16:294-301.
37. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reducedby suppressionofsubclinical cytomegalovirus infection. Transplantation. 2006;82:398-405.
38. Simmonds J, Fenton M, Dewar C, et al. Endothelial dysfunction and cyto-megalovirus replication in pediatric heart transplantation. Circulation. 2008;117:2657-2661.
39. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741.
40. Hocker B, Bohm S, Fickenscher H, et al. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int. 2012;25:723-731.
41. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5:2894-2900.
42. Asberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pedi-atric solid organ transplant recipients. Pediatr Transplant. 2014;18:103-111.